- Design
- Systematic review and meta-analysis of mostly retrospective cohorts and one phase 3 RCT
- Population
- 23 studies, 3,888 patients with metastatic PDAC after first-line FOLFIRINOX or NALIRIFOX
- Primary outcome
- Median OS and PFS from second-line initiation
- Effect
- Median OS 7.57 months (6.00–9.55); PFS 3.18 months (2.74–3.68); ORR 11.6%
FOLFIRINOX and NALIRIFOX are now standard first-line options for fit patients with metastatic pancreatic cancer, but most second-line evidence was gathered after gemcitabine. A meta-analysis in the Journal of Gastrointestinal Cancer (28 September) pooled 23 studies, 3,888 patients, treated second-line after a triplet.
Median overall survival from the start of second-line treatment was 7.6 months (95% CI 6.0 to 9.6) and median progression-free survival 3.2 months. About 12% responded and 48% had disease control. Gemcitabine-based combinations outperformed monotherapy, especially in patients with ECOG 0–1, and performance status was the strongest predictor of outcome. The one phase 3 trial, GEMPAX, showed better progression-free survival and response with gemcitabine plus paclitaxel than gemcitabine alone, but no overall survival gain.
Most data are retrospective, so the comparison between regimens is confounded by who was fit enough for a combination. The practical answer is to offer a gemcitabine-based combination to patients who remain ECOG 0–1, give realistic figures — months, not years — and move early to best supportive care for patients whose performance status has fallen.
- Consider a gemcitabine-based combination second line for patients with ECOG 0–1 after FOLFIRINOX.
- Weigh monotherapy or best supportive care when performance status has declined.
- Share realistic benchmarks: median survival about 7.6 months from second-line start.
- Involve palliative care early, alongside any second-line treatment.
Why it matters
It gives the first contemporary benchmark for a decision oncologists face with most patients who progress.
Don't overread it
Largely retrospective data; the only phase 3 trial showed no overall survival benefit for the combination.
The statistics, in plain English
Pooled medians from mostly retrospective cohorts describe typical outcomes, not the effect of one treatment over another. The advantage of combinations partly reflects that fitter patients receive them. GEMPAX, the only randomised comparison, did not show longer survival.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free